MedTrace Logo

Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS)

NCT01895764 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2026-04-03

No results posted yet for this study

Summary

The purpose of this study is to determine if association of methotrexate with adalimumab leads to decrease immunogenicity beside adalimumab alone in Ankylosing Spondylitis.

Conditions

Interventions

DRUG

Adalimumab

adalimumab, subcutaneous injection, 40mg every 2 weeks, week 0 until week 26

DRUG

Methotrexate

methotrexate, subcutaneous injection, 10mg per week, week -2 until week 26

Sponsors & Collaborators

  • University Hospital, Tours

    lead OTHER

Principal Investigators

  • Emilie DUCOURAU, MD · CHRU de TOURS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-20
Primary Completion
2015-04-27
Completion
2015-04-27

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01895764 on ClinicalTrials.gov